Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Stimulation magnétique transcrânienne répétitive guidée pour l'acouphène chronique

18 septembre 2026 mis à jour par: National University Hospital, Singapore

Stimulation Magnétique Transcranienne Neuronaviguée Comme Traitement Adjuvant Pour Les Acouphènes Chroniques

This study is testing whether a special type of brain stimulation called neuronavigated TMS can help reduce tinnitus (ringing in the ears). 50 people with tinnitus will each receive 20 treatment sessions - 10 real treatments and 10 sham treatments in random order, with a 2-week break between them. Before starting, participants get an MRI brain scan to guide where the stimulation device is placed. Questionnaires of measuring tinnitus severity will be asked four times throughout the study to determine to check the effect of TMS on treating tinnitus.

Aperçu de l'étude

Statut

Suspendu

Les conditions

Intervention / Traitement

Description détaillée

This study aims to investigate the beneficial effects of neuronavigated TMS (nTMS) in alleviating tinnitus symptoms and to establish safety and tolerability of nTMS in patients with tinnitus.

50 eligible subjects will be recruited and be randomized to receive 10 sessions of daily verum nTMS followed by 10 sessions of daily sham nTMS (verum-sham), or sham nTMS followed by verum nTMS (sham-verum). There will be a 2-week break between the two types of nTMS.

MRI will be conducted before the 1st session of nTMS for the TMS navigation system.

Outcome measures include Tinnitus Handicap Inventory (THI), Tinnitus Functional Index (TFI), and Tinnitus-Visual Analogue Scale (T-VAS). All assessment will be evaluated 4 times- before the 1st nTMS session, after the 10th nTMS session, before the 11th nTMS and after the 20th nTMS session.

Type d'étude

Interventionnel

Inscription (Estimé)

50

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Singapore, Singapour
        • Alexandra Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

21 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age 21-80 years old;
  2. Subjective tinnitus severity as per Tinnitus-Visual Analogue Scale of 1/10 and above (in any domain: sound, distress, Quality of Life)

Exclusion Criteria:

  1. Pregnancy;
  2. Any metal implants inside the body that are contraindications of MRI scan;
  3. Cardiac pacemakers;
  4. Epilepsy with recurrent seizures;
  5. Cognitively impaired patients will be excluded;
  6. Claustrophobia;
  7. Uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina;
  8. Major depression and a history of psychotic disorders;
  9. Terminal diagnosis with life expectancy <=1 year.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: real-sham

Subjects will receive 10 sessions of real nTMS, 5 times a week for 2 weeks, followed by 10 sessions of sham nTMS, 5 times a week for 2 weeks. There will be a 2-week break between the 2 types of nTMS.

Each session of rTMS (real or sham) consists of 1200 stimulations/day, conducted at once a day for five consecutive days (from Monday to Friday).

For sham stimulation, the TMS coil will still centre on the same scalp position, but it was tilted to 90° so that scalp contact and discharging noise were similar, but the magnetic field did not reach cortical neurons at a biologically active level.

The localization of the rTMS stimulation site (left Temporal Cortex) will be directed by a neuronavigation system imported with subject's MRI scan imaging to ensure the accuracy of rTMS stimulation area.

Expérimental: sham-real

Subjects will receive 10 sessions of sham nTMS, 5 times a week for 2 weeks, followed by 10 sessions of real nTMS, 5 times a week for 2 weeks. There will be a 2-week break between the 2 types of nTMS.

Each session of rTMS (real or sham) consists of 1200 stimulations/day, conducted at once a day for five consecutive days (from Monday to Friday).

For sham stimulation, the TMS coil will still centre on the same scalp position, but it was tilted to 90° so that scalp contact and discharging noise were similar, but the magnetic field did not reach cortical neurons at a biologically active level.

The localization of the rTMS stimulation site (left Temporal Cortex) will be directed by a neuronavigation system imported with subject's MRI scan imaging to ensure the accuracy of rTMS stimulation area.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Tinnitus Handicap Inventory (THI)
Délai: Week 0

THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic.

Week 0
Tinnitus Handicap Inventory (THI)
Délai: Week 3

THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic.

Week 3
Tinnitus Handicap Inventory (THI)
Délai: Week 6

THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic.

Week 6
Tinnitus Handicap Inventory (THI)
Délai: Week 7

THI consists of a 25 items which evaluate the subjective burden of tinnitus under a three-response system: yes (score = 4), sometimes (score = 2), or no (score = 0). THI scores of 18-36 are considered as mild tinnitus, 38-56 are considered moderate, and 58-76 are considered severe, while 78-100 are considered catastrophic.

Week 7

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Tinnitus Functional Index (TFI)
Délai: Week 0

Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress.

Week 0
Tinnitus Functional Index (TFI)
Délai: Week 3

Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress.

Week 3
Tinnitus Functional Index (TFI)
Délai: Week 6

Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress.

Week 6
Tinnitus Functional Index (TFI)
Délai: Week 7

Tinnitus Functional Index (TFI) is a 25-item questionnaire with a 10-point Likert scale covering eight underlying dimensions: (a) intrusiveness of tinnitus; (b) sense of control; (c) cognitive interference; (d) sleep disturbance; (e) auditory difficulties; (f) interference with relaxation; (g) quality of life; and (h) emotional distress.

Week 7
Tinnitus-Visual Analogue Scale (T-VAS)
Délai: Week 0

T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus.

Week 0
Tinnitus-Visual Analogue Scale (T-VAS)
Délai: Week 3

T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus.

Week 3
Tinnitus-Visual Analogue Scale (T-VAS)
Délai: Week 6

T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus.

Week 6
Tinnitus-Visual Analogue Scale (T-VAS)
Délai: Week 7

T-VAS is a clinical scale of the severity of tinnitus in loudness (sound), distress, and Quality of Life (QoL). The minimum value is 0 and the maximum value is 100. A higher score indicates a worse outcome, as it reflects greater perceived tinnitus loudness or severity. A score of 0 represents no tinnitus, while a score of 100 represents the worst imaginable tinnitus.

Week 7

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Les enquêteurs

  • Chercheur principal: Nicodemus Oey, MBBS, PhD, NUH

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 novembre 2025

Achèvement primaire (Estimé)

30 octobre 2027

Achèvement de l'étude (Estimé)

30 octobre 2027

Dates d'inscription aux études

Première soumission

20 février 2026

Première soumission répondant aux critères de contrôle qualité

20 février 2026

Première publication (Réel)

27 février 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

23 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

18 septembre 2026

Dernière vérification

1 décembre 2025

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner